Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Consultant Medical Oncologist: Oesophagogastric Cancer and Gene/Immunotherapy Research Christie Hospital NHS Foundation Trust with Salford Royal NHS Foundation Trust JOB DESCRIPTION Contents Page A) Christie Hospital NHS Foundation Trust 2 B) Salford Royal NHS Foundation Trust 3 C) University of Manchester: Cancer and Imaging Sciences 3 D) CRUK Department of Medical Oncology 4 E) Associated Documents 5 F) Clinical Facilities 6 G) Gastro–Intestinal Disease Orientated Group 7 H) Proposed Appointment 8 I) Indicative Timetable 10 J) Duties of the Post 10 K) Person Specification 11 L) Informal Visits and Selection Process 12 1 A) Christie Hospital NHS Foundation Trust Situated in a pleasant suburb, some 3 miles from Manchester city centre, the Christie Hospital and Holt Radium Institute was founded in 1932 and has grown to be the largest Cancer Hospital in the UK and one of the largest Cancer Centres in Europe covering a large population in North West England. In addition to the Christie Hospital itself, the Trust also comprises the North Western Medical Physics Department, one of the largest of its kind in the UK, and the Paterson Institute for Cancer Research, funded by Cancer Research UK. The Hospital is a designated teaching hospital of the University of Manchester and is a focal point of the Greater Manchester and Cheshire Cancer Network. All cancer-related specialties are fully operational and over 12,000 new patients with cancer are seen each year. The Christie site is the focal point of the recently established Manchester Cancer Research Centre. The Christie Hospital is composed of three clinical management divisions Networked Services Division – Director Dr Wendy Makin – includes the Departments of Medical Oncology, Clinical Oncology, Paediatric and Adolescent Oncology Cancer Centre Services – Director Miss Sarah O’Dwyer - Surgery, Anaesthetics, HDU, Endocrinology, Haematology. Clinical Support Services – Director Dr Jeremy Lawrence - Palliative Care, Radiology, Pathology. Other support services are provided by the Divisions of Finance, Nursing & Operations and Estates and Facilities. Both the Departments of Medical Oncology (Clinical Director: Dr Michael Leahy) and Clinical Oncology (Clinical Director: Dr Nick Slevin), have international reputations for their clinical work. All consultants are site specialised and common treatment policies are developed through the multi-disciplinary Disease Groups. Links to the cancer units are maintained through a number of peripheral and outreach clinics across the network. There are plans for the Christie to develop satellite centre’s at the Pennine Acute Trust and at Salford Royal NHS Foundation Trust so that ambulatory can be can be delivered more locally. The Christie Hospital NHS Foundation Trust is committed to cancer research and there was a successful Centenary Appeal that raised £25m for development of work at the Christie. Amongst other projects it is planned that £1m will go to an innovative treatment centre, £3m to the development of a Molecular Diagnostics Unit, which has already commenced, and £3.5m for the development of a Gene Therapy Centre. These, along with other developments, will further enhance the research standing of the Trust. The present Executive Directors of the Trust are: Caroline Shaw Ian Moston Dr Ron Stout Dr Chris Harrison Alison Norman Roger Spencer - Chief Executive Director of Finance and Business Development Medical Executive Director (Internal) Medical Director (External) Director of Nursing & Governance Chief Operating Officer 2 B) Salford Royal NHS Foundation Trust Salford Royal NHS Foundation Trust was licensed as a Foundation Trust from August 2006. It is a teaching hospital with 870 beds and provides District Hospital services for Salford. It is also a sub-regional centre for renal medicine, immunology, neurosciences and neonatal intensive care and there are many other highly specialised facilities including interventional radiology, intestinal failure, pain management, dermatology, urology, orthopaedics and rheumatology. The Trust is a teaching hospital for the University of Manchester Medical School and has an established Research and Development programme. Salford is the site of a major initiative and investment called the ‘SHIFT’ project (Salford Health Investment For Tomorrow) This project spans primary and secondary care and will involve novel modes of working and major investment in both primary and secondary care. On the hospital site this involved a PFI scheme to redevelop facilities. The Trust is a designated Associate Cancer Centre as outlined in the ‘Harrison’ Strategy for Greater Manchester, and as such is the identified sector centre for Oesophagogastric, Urological, Gynaecological and Haematology services. For these services it provides specialist services for the populations of Ashton, Wigan and Leigh, Bolton and Salford PCT’s. The Trust hosts the specialist services and MDT’s for Brain and Central Nervous system and Skin Cancers as well as providing a full range of other local cancers services. The Trust is working collaboratively with the Christie Trust to develop satellite Radiotherapy services on the Salford Royal site and to implement the Chemotherapy strategy. The Trust Board comprised of the Executive Directors of the Trust and is responsible for the overall performance of the Trust and delivery of its strategic and operational objectives. The following groups feed into the Trust Board. Strategy Advisory Group Clinical effectiveness Patient and Staff Experience Risk Management Finance and Performance The Trust has a clinical governance strategy, which describes key roles and responsibilities for staff providing services. The present Executive Directors of the Trust are David Dalton Dr Stephen Waldek Tony Whitfield Elaine Inglesby Raj Jain Simon Neville C) Chief Executive Medical Director Director of Finance Executive Nurse Director of Workforce and Corporate Affairs Director of Strategy and Development (and Executive lead for Cancer) University of Manchester: Cancer and Imaging Sciences Cancer and Imaging Sciences at the University of Manchester (Group Leader: Professor A Whetton) comprises a number of research groupings including the CRUK Department of Medical Oncology, Cancer Epidemiology, the Academic Department of Radiation Oncology and Imaging Sciences. There are close links with the Paterson Institute for 3 Cancer Research and a number of the Institute’s senior staff have honorary University posts within Cancer Studies which was rated 5* in the 2001 Research Assessment Exercise (RAE). The major grouping within Cancer Studies is the CRUK Department of Medical Oncology that is one of the largest in the country. The department has laboratories located within the Paterson Institute and annual grant support of about £2m per annum from the CRUK, the Kay Kendall Leukaemia Fund, AICR, BBSRC, EU and others. There is a wide range of clinical and laboratory research within the Department. The appointment of Professor Hawkins as CRUK Professor of Medical Oncology has led to an expansion of translational research activity particularly in the development of new therapies with the establishment of several major groups (Drug Development: Professor Malcolm Ranson; Anti-Angiogenic Therapy: Professor Gordon Jayson; Biological Immune and Gene Therapy: Professor Robert Hawkins). Overall, the areas of laboratory research within Medical Oncology comprise: growth factors and glycobiology (Professor J Gallagher, Professor G Jayson), breast biology (Professor A Howell and Dr Rob Clark), immunology and cancer vaccines (Professor R Hawkins closely linked with Professor P Stern), gene therapy (Professor R Hawkins and Dr D Gilham). Professor Ranson with Professor Caroline Dive lead Drug Development. The Hospital has a Statistics Department, directed by Mr. R Swindell, which offers support to clinicians involved in clinical studies and trials. In addition to the above links there are close links with groups in the Paterson Institute. The Paterson is a major Cancer Research UK Institute with £8M per year grant support and a broad range of basic and translational research. The research groups include: Bioinformatics - Crispin Miller Carcinogenesis -Geoff Margison Cell Division - Iain Hagan Cell Regulation - Nic Jones Cellular and Molecular Pharmacology - Caroline Dive Cell Signaling - Angeliki Malliri Functional Genomics and Cell Cycle Regulation - Karim Labib Immunology - Peter L. Stern Inositide Laboratory Nullin Divecha Leukaemia Biology - Tim Somervaille Stem Cell Biology - Georges Lacaud Stem Cell and Haematopoiesis - Valerie Kouskoff Stromal-Tumour Interaction Group: Akira Orimo The institute has excellent central services including molecular biology (sequencing, realtime PCR, Affymetrix Micro array), FACs analysis and sorting, image analysis and pharmacology. A major new Molecular Imaging Centre for translational studies which will provide stateof-the-art PET scanning facilities has been built with funding from the Wolfson Foundation and together with the large Oncology practice, extensive CRUK Phase I activities and the Paterson Institute it will facilitate mechanistic trials of novel agents. D) Cancer Research UK Department of Medical Oncology The CRUK Department of Medical Oncology is now one of the largest departments of cancer medicine in the UK. Professor Robert Hawkins is Director of Medical Oncology and the major remit of the department is to develop improved methods for cancer patient management. There are both clinical and laboratory scientific research components that are closely integrated with clinical research and service work. 4 The Department is based at the Christie Cancer Centre (Christie Hospital and Paterson Institute for Cancer Research) with a Breast Cancer Unit at Wythenshawe / Withington Hospital (University Hospitals of South Manchester) and a Thoracic Oncology Unit at Wythenshawe Hospital (Cardiothoracic Centre). More than 4,000 new cancer patients are seen each year by staff in the Department of Medical Oncology. The Department has links with Preston Oncology Centre and with the Department of Medical Oncology at Lancaster Royal Infirmary, which is included as part of the Medical Oncology SpR rotation (total 17 NTN’s). Consultant Medical Oncologists at Preston, Lancaster and Blackpool form part of the extended Department and have many common protocols with Manchester. Clinical Staff There are nineteen consultants in the department of Medical Oncology: Dr Anne Armstrong Dr Fiona Blackhall Dr Andrew Clamp Dr Jurjees Hassan Professor Robert Hawkins Professor Gordon Jayson Dr Michael Leahy Dr Paul Lorigan Dr Was Mansoor Dr Saifee Mullamitha Professor Tony Howell Professor John Radford Professor Malcolm Ranson Professor Nick Thatcher Dr Fiona Thistlethwaite* Dr Chan Ton* Dr Juan Valle Dr Andrew Wardley Dr Greg Wilson * - Breast Cancer – Link with Crewe - Lung Cancer - Ovarian and Gynaecological Oncology - Colorectal and Ovarian – link with Stepping Hill - Renal, Gastric and Immunotherapy Phase I Trials - Ovarian Cancer and Anti-Angiogenesis Phase I Trials - Sarcoma and Germ Cell Cancer – link with Oswestry - Melanoma and Lung Cancer - Upper GI and Carcinoid – link with South Manchester - Lower GI – link with Oldham - Breast cancer prevention - Lymphoma - Clinical Pharmacology - Lung Cancer - Oesophagogastric – link with Salford Royal - Lower GI – link with Crewe - Upper GI and HPB Cancer – link with North Manchester - Breast Cancer - Breast and Colorectal Cancer – link with Wigan locum posts There are also two linked posts in Wythenshawe Hospital – Dr Paul Taylor and vacancy (Lung Cancer Medical Oncology in the Pulmonary Oncology Unit). There are at present 10 Specialist Registrars, 8 SHO level posts. Clinical Research Fellows also participate in clinical activities, in addition to their laboratory research. There will be further posts developed as the Foundation programme rolls out. E) Associated Departments Clinical Oncology (Director Dr Nick Slevin) Clinical Oncology has 25 consultants and state of the art radiotherapy equipment along with a major research centre - The Wade Centre (Director Dr John Logue). The Clinical Oncology Division provides a service to Greater Manchester and North Cheshire through clinics (mainly weekly) staffed by its consultants in every main town in the area. A good liaison exists between the divisions of Clinical Oncology and Medical Oncology. Many of the clinical protocols are run jointly between the two departments and there are excellent opportunities at Specialist Registrar level to participate in joint teaching programmes. 5 Haematological Oncology Dr James Cavet, Dr Effie Liakopoulou , Dr Adrian Bloor and Dr Mike Dennis run a major transplant unit with 18 dedicated beds. Appointment of a Professor and Senior Lecturer are planned. F) Clinical Facilities Wards 1. 2. 3. 4. 5. 6. 7. General medical oncology wards – 40 inpatient beds available on modern wards with excellent routine facilities. 16 inpatient chemotherapy beds shared with Clinical Oncology. Used for shorter stay chemotherapy treatments, these beds are not normally open at weekends. The Adult Leukaemia Unit (ALU), with 18 beds available for the care of adult patients with haematological malignancy and lymphoma requiring myeloablative therapy with haemopoietic rescue. Chemotherapy Day Ward (ward 5). Used for longer day case chemotherapy treatments, with 9 inpatient beds available if necessary. An 8 bedded Critical Care Unit opened in 2007 and provides hospital wide support. The Christie has a private patient facility (Nathan House) that has 18 rooms. These are primarily for private patients but are made available to NHS patients if the need arises. The Phase I/II Unit (Derek Crowther Unit) provides dedicated clinical research facilities and is one of the largest in the UK. There are plans to double the size of the unit and to integrate it with enhanced chemotherapy facilities. A wide range of cancers are managed in these ward facilities and practical training in all aspects of cancer medicine is provided at SHO/SpR levels. Special facilities include two cell separators for leukapheresis and plasmapheresis. Outpatient facilities Routine medical oncology clinics are held daily at the Christie Hospital for new patients and follow up. There are specialised cancer site related collaborative clinics and routine outpatient clinics. Several of the Consultants visit DGH’s within the Greater Manchester and Cheshire Cancer Network to undertake clinics for new and follow-up patients. Satellite centres for Radiotherapy and Chemotherapy are planned in Oldham and Salford and by 2012 are expected to provide around a third of networked radiotherapy and chemotherapy services focusing on more common tumours types. Similarly chemotherapy facilities are being upgraded on the Christie site with a £35 M state of the art chemotherapy/research unit planned to be built commencing in 2008. Specialist nurse facilities Teams of specialist chemotherapy and research nurses work alongside the clinicians. These nurses have special expertise and training in the administration of chemotherapy. Specialist nurses are also trained to insert i.v. long lines, carry out bone marrow aspiration/trephine procedures, operate the cell separators for leukapheresis and provide psychological support and counselling. Other departments The Department of Histopathology provides a regional cancer service. 6 The Department of Diagnostic Radiology has two whole body spiral CAT scanners, two MR scanners and a state of the art PET-CT scan in addition to standard radiological and radionucleide imaging facilities. The Department of Psychological Medicine is involved in collaborative research projects concerning psychological assessment and counseling in the context of clinical trials and is responsible for staff training in aspects of psychological support. Clinical and Laboratory Scientific Research A wide range of clinical research studies are in progress. The breast, lung and GI research groups are major contributors to national and international trials of new treatments. These include Phase I/II and III chemotherapy studies, combined surgery, radiotherapy and chemotherapy studies and patient evaluation studies (staging procedures, psychological assessment etc). A special interest is taken in the development of new biological therapies particularly anti-angiogenic therapies (lead by Professor Gordon Jayson) and gene/immunotherapies (lead by Professor Robert Hawkins). The Derek Crowther Unit was opened in 2003 (lead clinician Professor Malcolm Ranson) and provides excellent clinical research facilities for early phase clinical trials. Excellent computer facilities are available within the Medical Oncology Division and there is a close association with the Department of Medical Statistics. Data managers are in post to help handle clinical and laboratory research data. Training is given in this important aspect of clinical research. Travel facilities Support is available for participation in research meetings. Administrative facilities The post holder will have office accommodation with computer, intranet and internet. There will be secretarial support appointed to support the post. G) Gastro-intestinal Disease Orientated Group The Gastrointestinal DOG also provides comprehensive treatment for GI Cancers and has a broad ranging laboratory and clinical research portfolio. The DOG group covers surgical and non-surgical oncology and the core members (and their primary clinical interest) are: Oncologists Dr Paul Burt – Dr Corinne Finn Prof. Robert Hawkins – Dr Ed Levine Dr Mark Saunders – – Dr Juan Valle – Dr Greg Wilson Dr Jurjees Hassan Dr Saifee Mullamitha Dr Was Mansoor Dr Fiona Thistlethwaite Dr Chan Ton - Oesophageal Radiotherapy Oesophageal Radiotherapy Renal/Oesophago-Gastric systemic therapy Phase I trials of gene/immunotherapy Colorectal/anal chemo/radiotherapy Colorectal/anal chemo/radiotherapy, Gastric Adjuvant Radiotherapy Colorectal, cholangiocarcinoma, hepatocellular carcinoma, pancreatic cancer neuroendocrine Colorectal Chemotherapy Colorectal Chemotherapy Colorectal chemotherapy Oesphago-Gastric Chemotherapy and Carcinoid Oesphago-Gastric Chemotherapy and Gene /Immunotherapy Research Colorectal Chemotherapy 7 Surgeons Miss Sarah O’Dwyer Mr. David Sherlock Mr. Ian Welch Mr. Malcolm Wilson H) – – – – Colorectal and pelvic malignancy Hepatobiliary Surgery Upper GI Surgery Colorectal and pelvic malignancy The proposed appointment This NHS Consultant Medical Oncologist post forms part of the expansion of the oesophagogastric cancer practice at the Christie Hospital NHS Foundation Trust and the expansion of services at Salford Royal NHS Foundation Trust for oesophagogastric cancer. The post is designed to spend approximately 50% of the time providing a clinical service and 50% of the time undertaking research. The research aspect will link with the Gene and Immunotherapy research programmes. Linking with the existing consultants specialising in oesophagogastric cancer – Professor Robert Hawkins and Dr Was Mansoor the post-holder will be expected to help develop the service and the clinical trials portfolio of the oesophagogastric group both at the Christie and in North West Manchester. The post will combine clinical work at the Christie with work at Salford Royal NHS Foundation Trust. The job plan anticipates 2 future sessions at Hope Hospital, and 8 sessions at the Christie Hospital. Currently there are 3 or 4 middle grade doctors (SpRs or ST3 – 6) attached to the GI team and the post holder will take an equal role with the other GI medical oncology consultants in supervising these doctors and also the junior grade medical staff in clinic and on the ward in the care of their patients The post holder will be expected to take part in the Consultant on-call rota (1:16). Expected patient numbers About 600 new upper GI patients are seen by medical oncologists in the Christie network and this post is expected to see about a third of these of these (150-200 new patients per year). These patients will come from Salford Royal NHS Foundation Trust, Wigan, Bolton and surrounding areas. The remainder of the oesophagogastric cancer practice will be covered by Dr Was Mansoor (South) Professor Robert Hawkins (North East). Research Activity Clinical Research The GI DOG has an extensive clinical trials portfolio. A major aim of this appointment is to expand the range of trials in oesophagogastric cancers. The development of the NCR network (lead clinician Professor Nigel Bundred) should facilitate trial recruitment. Professor John Radford as Trust R&D Director is leading the development of clinical trials infrastructure in the Trust. Translational Research A major component of the post will relate to the development of translational research within the gene and immunotherapy groups (Head: Professor Robert Hawkins). Important areas of research include: Engineered T cell Therapy (leads Dr David Gilham and Dr Eleanor Cheadle) Molecular Monitoring of Biological Therapy (Dr Dominic Rothwell) Clinical Immunological Evaluation (Dr Eyad Elkord) Target Discovery/Definition (Professor Peter Stern) GMP Cell Production (Dr Ryan Guest/Dr Eric Austin) – Based at the National Blood Service in Manchester. The group has an excellent track record of success in translational research having developed 5T4 from initial target discovery through to two products in Phase III clinical trials. Current focus is on developing cellular therapy and manipulating immune 8 regulation. As well as national links through Cancer Research UK and the Experimental Cancer Medicine Centres the group has international links with many key groups in Europe and worldwide. Key amongst these is the ATTACK project which is a major EU FP6 integrated project with 12 million Euro funding form the EU and a remit to optimise pre-clinical development of engineered T cells to target cancer. The project has 17 partners and is lead from Manchester (Co-ordinator Professor Robert Hawkins). The post holder will be expected to link with these groups to facilitate translational research in these and related fields. The development of other novel approaches to gene and immunotherapy is encouraged. There is good laboratory and clinical infrastructure to support this research. Clinical facilities will be enhanced by the development of a dedicated research ward as part of the chemotherapy research development (see above – funding from Cancer Research UK, Wolfson Foundation and Department of Health). Likewise a more comprehensive GMP cell therapy unit is planned to be developed combining Stem Cell Processing and translational research and will facilitate cell therapy approaches. Teaching Commitment There is an excellent Specialist Registrar training schemes in both Clinical and Medical Oncology. In all there are 12 SpR posts on the Medical Oncology Programme, 19 SpR posts in Clinical Oncology and a variable number of Clinical Research Fellows. Management/Audit The appointee will be expected to engage in audit of their own practice and contribute to departmental audit. They will be expected to accept roles and responsibilities within the Medical Oncology directorate in discussion with the Clinical Director within the capacity of their job plan. Continuing Medical Education The Trust supports the requirements for continuing medical education as laid down by the Royal College of Physicians and is committed to providing time and financial support for these activities. Proposed Sessions As indicated, this is a new post and the prospective candidates will need to discuss their specific clinical interests with both Trusts. This Job Plan is indicative and may evolve as oncology services across the network develop. Research funding is guaranteed for 4 years from a CRUK programme grant. After 2011 it would be expected that the post will be generating sufficient research income to account for the protected research sessions. Such income could be through activity / tariff or through grants. Should funding from these sources be insufficient then the post holder will have the option of transferring to a full clinical job plan with 7.5 PAs DCC and 2.5 PAs SPA with an expectation of generating sufficient activity to support the post. 9 Job Plan Direct Clincal Care 2 x OP Clinics Christie Hospital 1 x Research OP clinic – Christie Ward Rounds – Christie Admin MDTs (Salford Royal) Travel Programmed Activity* 2 1 0.75 1.00 0.75 0.25 (5.75) Other Activity Teaching Research/Res Admin CPD 0.25 3.25 0.75 TOTAL *A programmed activity is 4 hours I) (4.25) 10 Indicative Timetable The following is the proposed timetable. Monday ( Christie ) Tuesday ( Christie ) Wednesday (Christie) Thursday ( Christie ) Friday (Christie / Hope) 9 am to 12am Joint Ward Round Hawkins/Mansoor CPD/Admin 9:00 to 13:00 Joint Oesophagogastric Clinic Mansoor/Welch 9:00 to 13:00 Joint Research Clinic DCU Hawkins CPD / Admin Research Research 14:00 to 16:00 Oesophagogastric MDT Hope Hospital and ward visits 16:00 Consultant Meeting x 2/month Joint New patient clinic Christie Mansoor Immunotherapy Research Meeting Research The post holder will be expected to be on-call for Medical Oncology – currently it is a 1:16 rota. J) Duties of the Post 1. Main Duties: To be a consultant at the Christie Hospital NHS Foundation Trust. This will involve close liaison with other members of the multidisciplinary team. A major role of this new post will be to develop and implement evidence based best practice for patients treated at Christie and Salford. 2. Clinical Management: To work closely with other medical colleagues in the fields of oesophagogastric cancer. An important role of the consultant will be to have direct involvement in the day-to-day clinical management of patients. This post holder will create a close interface between the laboratory and clinical medicine facilitating the continued development of clinically relevant, evidence-based protocols. 10 3. Clinics: The post holder would be required support 3 clinics per week. 4. Protocols: The post holder will be expected to revise and develop evidence-based protocols for patients. He/she will be expected to undertake the administrative duties associated with the care of these patients. 5. Professional Development: He/she will maintain a level of continuing professional development consistent with the recommendations of the Royal College of Physicians. Appropriate arrangements for study leave will be made in conjunction with colleagues. A fund, administered by the Clinical Director for the support of study leave, exists within the Trust. The post-holder will also be required to undergo annual appraisal. 6. Teaching Commitment: a) Undergraduate The appointee will be expected to contribute to the undergraduate teaching of medical students on clinical topics. b) Postgraduate The hospital has a busy postgraduate teaching programme and staff are often requested to lecture on oncology topics. In total these would be expected to account for one session per month. 7. Junior Doctor Training: The post holder will be expected to contribute actively to the training of SHO’s in medical oncology. The post holder will also be expected to help in the training of nursing and multi-disciplinary staff in both in-patient and outpatient departments. 8. Clinical Governance: The post-holder will be expected to participate in all relevant aspects of clinical governance, including maintaining up to date protocols, guidelines and clinical audit, under the supervision of the other consultants in the unit. 9. Audit: The appointee will play a full role in clinical audit as a member of the Christie Hospital Medical Staff Committee. 10. Research: As indicated approximately up to 42.5% of the time is designated for research. The aim is to develop trials in oesophago-gastric cancer and to develop translational research in gene and immunotherapy. 11. On Call: The post attracts an on call commitment. 11 K) PERSON SPECIFICATION POST: CONSULTANT MEDICAL ONCOLOGIST; OESOPHAGOGASTRIC CANCER AND GENE/IMMUNOTHERAPY RESEARCH REQUIREMENTS Qualifications ESSENTIAL MBBS or equivalent MRCP or equivalent Certificate of completion of subspecialty training in Medical Oncology, or evidence of completion within 6 months of the date of the Appointments Committee DESIRABLE Training & Experience Evidence of wide experience of general and oncological medicine Evidence of extensive training in the management of oesophagogastric cancers Training in aspects of gene and or immunotherapy An interest in teaching medical, nursing and allied health professional staff Experience of teaching undergraduate / postgraduate trainees Interest in teaching / education Teaching the Teachers course or equivalent Academic / Research achievements Able to demonstrate continuing research interest and activity PhD in a relevant area of research Experience of Developing Immunological and/or Gene Therapies Recent articles in peer-reviewed publications The ability to initiate design and supervise clinical research Personal Skills Clinical leadership and people management skills, with the ability to motivate staff Demonstrable interpersonal skills Evidence of excellent written and oral communication skills Flexible approach to work The ability to work as part of as multi-disciplinary team Good time management skills, with the ability to handle competing demands Personal Circumstances Reliable work record Good health record Living within reasonable traveling distance from the hospital 12 TERMS AND CONDITIONS OF SERVICE PAY The New Consultant Contract is applicable to this post. CONFIDENTIALITY The post-holder must maintain the confidentiality of information about patients, staff and other health service business. HEALTH AND SAFETY Employees must be aware of the responsibilities placed on them under the Health & Safety at Work Act (1974), to ensure that the agreed safety procedures are carried out to maintain a safe environment for employees. RISK MANAGEMENT All staff have a responsibility to report all clinical and non-clinical accidents or incidents promptly and when requested to co-operate with any investigation undertaken. EQUAL OPPORTUNITIES The Trust has adopted an equal opportunities policy and it is the duty of every employee to comply with the detail and spirit of the policy CONFLICT OF INTEREST The Trust is responsible for the service for the patients in its care meets the highest standards. Equally, it is responsible for ensuring that staff do not abuse their official position to gain or to benefit their family or friends. The Trust’s standing orders require any officer to declare any interest, direct or indirect with contracts involving the Trust. Staff are not allowed to further their private interest in the course of their NHS duties. NO SMOKING The Trust operates a no smoking policy. Anyone who wishes to smoke may do so only in one of the designated smoking areas at a time agreed with their line manager. MEDICAL EXAMINATION All appointments with Christie Hospital NHS Foundation Trust are subject to pre-employment health screening. L) Informal Visits and the selection process Interested candidates are encouraged to discuss the post with one or more of the following people. For Christie Hospital: Dr Michael Leahy, Clinical Director for Medical Oncology, may be contacted via his secretary, on 0161 446 8384 or [email protected] Professor Robert Hawkins, Programme Lead for Immnuo / Gene Therapy programme, may be contacted via his secretary, Roberta Ellis, on 0161 446 3473 or [email protected] Dr Wendy Makin , Divisional Director for network Services Division can be contacted on 0161 446 3260 or [email protected] 13 Ben Fryer, Clinical Service Manager for Medical Oncology can be contacted on 0161 446 8169 at [email protected] 14